[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU5632300A - Methods of inhibiting muscle atrophy - Google Patents

Methods of inhibiting muscle atrophy

Info

Publication number
AU5632300A
AU5632300A AU56323/00A AU5632300A AU5632300A AU 5632300 A AU5632300 A AU 5632300A AU 56323/00 A AU56323/00 A AU 56323/00A AU 5632300 A AU5632300 A AU 5632300A AU 5632300 A AU5632300 A AU 5632300A
Authority
AU
Australia
Prior art keywords
methods
muscle atrophy
inhibiting muscle
inhibiting
atrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56323/00A
Inventor
David J. Glass
Christian Rommel
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU5632300A publication Critical patent/AU5632300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU56323/00A 1999-07-07 2000-06-22 Methods of inhibiting muscle atrophy Abandoned AU5632300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14285799P 1999-07-07 1999-07-07
US60142857 1999-07-07
PCT/US2000/017173 WO2001004354A2 (en) 1999-07-07 2000-06-22 Use of ras inhibitors of inhibiting muscle atrophy

Publications (1)

Publication Number Publication Date
AU5632300A true AU5632300A (en) 2001-01-30

Family

ID=22501570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56323/00A Abandoned AU5632300A (en) 1999-07-07 2000-06-22 Methods of inhibiting muscle atrophy

Country Status (5)

Country Link
EP (1) EP1192281A2 (en)
JP (1) JP2003504351A (en)
AU (1) AU5632300A (en)
CA (1) CA2378982A1 (en)
WO (1) WO2001004354A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085364A1 (en) * 2001-04-25 2002-10-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
ES2770067T3 (en) 2004-05-11 2020-06-30 Ncardia Ag Drug discovery based on differentiated cells in vitro
US20110313027A1 (en) * 2008-08-13 2011-12-22 Zador Ernoe Methods and substances for stimulating muscle regeneration
JP5866126B2 (en) * 2010-11-09 2016-02-17 サーコーティン ダイアグノスティックス エルエルシー BIN1 expression as a marker of skeletal muscle mass and neurological status
WO2013049666A1 (en) 2011-09-30 2013-04-04 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
WO2015085097A1 (en) 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3265811B1 (en) 2015-03-02 2022-10-26 Sarcotein Diagnostics LLC 13+/17+ bin1 expression as a marker of cardiac disorders
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Also Published As

Publication number Publication date
WO2001004354A2 (en) 2001-01-18
CA2378982A1 (en) 2001-01-18
EP1192281A2 (en) 2002-04-03
JP2003504351A (en) 2003-02-04
WO2001004354A3 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AUPQ419099A0 (en) Novel compositions and methods
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU2557500A (en) Methods of making compounds
AU3791601A (en) Treatment of coal
IL146530A0 (en) Method of inhibiting neurotrophin-receptor binding
IL146529A0 (en) Method of inhibiting neurotrophin-receptor binding
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU6564600A (en) Copolymers of acryloyloxyalkylamino compounds
AU6690300A (en) Copolymers of acryloylaminoalkyl compounds
HUP0201642A3 (en) Preparation of substituted piperidin-4-ones
AU5632300A (en) Methods of inhibiting muscle atrophy
AU7715300A (en) Method of preventing osteoporosis
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU4369000A (en) Inhibition of complement action
AU5434599A (en) Exerciser
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU6553998A (en) Methods for inhibiting bacterial cytotoxicity
AU1601801A (en) Methods of preparing crna
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU4428900A (en) Novel injectable muscle relaxant formulations
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
AU7666000A (en) Method of protecting wood

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase